What are the indications for cefepime and how does its antimicrobial coverage compare to ceftazidime and meropenem?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cefepime Indications and Coverage Comparison

FDA-Approved Indications for Cefepime

Cefepime is FDA-approved for moderate to severe pneumonia, empiric therapy for febrile neutropenia, complicated and uncomplicated urinary tract infections, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections (in combination with metronidazole). 1

Specific pathogens covered include:

  • Pneumonia: Streptococcus pneumoniae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species
  • UTIs: E. coli, K. pneumoniae, Proteus mirabilis
  • Skin infections: Methicillin-susceptible S. aureus (MSSA), Streptococcus pyogenes
  • Intra-abdominal infections: E. coli, viridans streptococci, P. aeruginosa, K. pneumoniae, Enterobacter species, Bacteroides fragilis (when combined with metronidazole)

Coverage Comparison: Cefepime vs Ceftazidime vs Meropenem

Gram-Negative Coverage

Cefepime demonstrates superior activity against Gram-negative organisms compared to ceftazidime, particularly against nosocomial pathogens and ESBL producers. 2

Key differences:

  • Ceftazidime is no longer reliable for empiric monotherapy due to decreasing potency against Gram-negative organisms 2
  • Cefepime shows 96% susceptibility against Gram-negative bacilli versus only 67% for ceftazidime 3
  • Against nosocomial K. pneumoniae, cefepime is >3 times more active than ceftazidime 3
  • Meropenem remains slightly superior to both, with only 3% resistance among Gram-negatives 3

Pseudomonas aeruginosa Coverage

All three agents provide anti-pseudomonal coverage, which is essential for empiric therapy in high-risk infections 2, 4, 5:

  • Carbapenems (including meropenem) show 92.5% susceptibility against P. aeruginosa from cystic fibrosis patients
  • Cephalosporins (cefepime and ceftazidime) show 77.6% susceptibility 6
  • For empiric P. aeruginosa coverage in CAP or HAP, options include cefepime 2g q8h, ceftazidime 2g q8h, or meropenem 1g q8h 4, 5

Gram-Positive Coverage

Cefepime has significantly better Gram-positive activity than ceftazidime, particularly against streptococci. 2, 7

  • Ceftazidime has poor activity against Gram-positive pathogens including streptococci 2
  • Cefepime MIC90 against MSSA is 1.5 mcg/mL versus 4 mcg/mL for ceftazidime 3
  • Both cefepime and ceftazidime achieve 100% susceptibility against MSSA 3
  • Neither agent covers MRSA, enterococci, or C. difficile 8
  • Meropenem provides broader Gram-positive coverage than either cephalosporin

ESBL and Resistant Organisms

For ESBL-producing Enterobacterales, meropenem is preferred over cefepime or ceftazidime. 2

  • Cefepime shows better stability against beta-lactamases than ceftazidime 8, 3
  • Against nosocomial K. pneumoniae with high ESBL rates (69%), cefepime maintains better activity than ceftazidime 3
  • For carbapenem-resistant Enterobacterales (CRE), newer agents like ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-relebactam are required 9

Clinical Context and Safety

Febrile Neutropenia

Cefepime remains an acceptable first-line monotherapy for febrile neutropenia despite prior mortality concerns. 2

The FDA meta-analysis found no statistically significant increase in 30-day mortality with cefepime (RR 1.20; 95% CI 0.82-1.76) 2. Recommended dose: 2g IV q8h for 7 days or until neutropenia resolves 1.

Hospital-Acquired Pneumonia

For HAP without MRSA risk factors, cefepime 2g IV q8h is recommended as monotherapy 5. For high mortality risk or recent antibiotic use, combine with an aminoglycoside or fluoroquinolone and add MRSA coverage 5.

Important Caveats

  • Cefepime has been excluded from WHO essential medicines recommendations due to concerns about increased mortality and redundancy with other cephalosporins 10
  • For intra-abdominal infections, WHO guidelines favor ceftriaxone over cefepime 10
  • Neurotoxicity risk: Cefepime may cause neurotoxicity, especially in renal impairment; dose adjustment required for CrCl ≤60 mL/min 1
  • Recent data suggest empiric cefepime for ceftriaxone-resistant E. coli and K. pneumoniae may delay clinical stability compared to meropenem, even when cefepime-susceptible 11

Practical Algorithm

For empiric therapy selection:

  1. Community-acquired infections, no ESBL risk → Cefepime preferred over ceftazidime (broader coverage)
  2. Nosocomial infections, ESBL suspected → Meropenem preferred over both cephalosporins
  3. Febrile neutropenia → Cefepime, meropenem, or piperacillin-tazobactam equally acceptable 2
  4. Known CRE → Avoid all three; use ceftazidime-avibactam, meropenem-vaborbactam, or polymyxin-based combinations 9
  5. Renal impairment → Cefepime or ceftazidime preferred over meropenem (easier dose adjustment without nephrotoxicity concerns) 7

References

8
Research

Cefepime: a new fourth-generation cephalosporin.

American journal of hospital pharmacy, 1994

Related Questions

What are the differences between cefepime and meropenem regarding spectrum of activity, dosing, and adverse effects?
In a patient with ICU sepsis, what organisms does each of the following antibiotics cover: tobramycin, cefepime, and ceftaroline?
Is it appropriate to give cefepime and meropenem together?
What is the best antibiotic for a patient with a cannula site infection, considering potential allergies to cephalosporins (e.g. cefazolin) or penicillins?
What cefepime dosing regimen should be used for an 82-year-old, 83-kg patient with a creatinine clearance of 69 mL/min who has sepsis?
For a patient currently stable on oral risperidone 4 mg daily who wishes to switch to the long‑acting injectable formulation (Risperdal Consta), what dose should be used?
In a patient with a complicated urinary tract infection and septic shock who is already receiving cefepime and now has gram‑positive rods isolated, what additional antimicrobial therapy should be added?
Can ivabradine be prescribed for a patient with sinus tachycardia and preserved left ventricular ejection fraction?
What are the key components of the clinical diagnosis of interstitial lung disease, including the relevant history and physical examination findings?
In a male patient with a CHA₂DS₂‑VASc score greater than 1, should apixaban (Eliquis) be continued at 5 mg twice daily or reduced to 2.5 mg twice daily?
What treatments are recommended for cardiac autonomic neuropathy presenting with heart palpitations?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.